ERBB2 and breast carcinoma: HER2-targeted therapy has revolutionized the treatment of HER2+ breast cancer (BC), and its use in the curative setting has changed the natural course of the disease, achieving outcomes similar to those of patients with HER2-negative disease for a historically poor prognosis subpopulation [2].